InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,346.99
(
-0.11%
)
US TECH 100
18,488.00
(
-0.25%
)
Dow Jones
38,798.99
(
-0.22%
)
Brent Oil
79.40
(
0.00%
)
Bitcoin
69,344.05
(
0.02%
)
Post# of 19309
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 832
Posts 119787
Boards Moderated 17
Alias Born 09/05/2002

DewDiligence

Member Level

Re: RufusT post# 8825

Saturday, 03/08/2008 12:12:00 AM

Saturday, March 08, 2008 12:12:00 AM

Post# of 19309
Re: GTC’s unnamed mAb FoB’s

>The four or five mabs coming off patent I take it are Rituxan (targeted by the CD20 project), Avastin and other cancer mabs?<

Avastin is probably not one of them because it has a considerable amount of US patent time remaining.

Other than Rituxan, the likely mAb FoB’s that GTC is thinking about include Herceptin, Remicade, and Enbrel, IMO. Erbitux could be one too.

All of these meet the “large volume” rationale for transgenic production. (Enbrel is strictly speaking not a mAb, but it is usually thought of as one.) Regards, Dew

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up